E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial

Reema Thottol, Ancy George, Laxmi G.

Abstract
Background: The ever-increasing prevalence of diabetes has led to a higher incidence of progression into complications including nephropathy. Diabetic kidney disease (DKD) is a chronic condition that is managed with renin-angiotensin-aldosterone system blockers which retard its progression. Pentoxifylline as an add-on therapy has been tried for reducing
DKD.

Aims and Objectives: The aims of this study were to study the safety and efficacy of pentoxifylline added on to an angiotensin II receptor blocker (ARB) to reduce the progression of the disease condition in diabetic nephropathy (DN) patients over 1 year.

Materials and Methods: It is a randomized open-label study conducted in the Department of Nephrology, of a tertiary care center for 1 year. Type 2 diabetes patients with DN who satisfied the eligibility criteria were randomized into pentoxifylline added on to ARB or ARB alone and followed up for urine albumin-creatinine ratio (ACR) and serum tumor necrosis factor (TNF)-alpha.

Results: Twenty-six patients were recruited and completed the study. Urine ACR was significantly low in the pentoxifylline group compared to the ARB alone group (P = 0.021). Serum TNF-α was decreased in the pentoxifylline group in comparison to the ARB alone group (P = 0.06).

Conclusion: Pentoxifylline caused significant lowering of urinary ACR and urine TNF-α for 4 months.

Key words: Diabetic Nephropathy; Pentoxifylline; Urine Albumin/Creatinine Ratio; Urine Tumor Necrosis Factor-α


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Reema Thottol
Articles by Ancy George
Articles by Laxmi G
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Thottol R, George A, G L. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. Natl J Physiol Pharm Pharmacol. 2022; 12(6): 823-827. doi:10.5455/njppp.2022.12.04159202221042022


Web Style

Thottol R, George A, G L. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. https://www.njppp.com/?mno=8105 [Access: August 03, 2022]. doi:10.5455/njppp.2022.12.04159202221042022


AMA (American Medical Association) Style

Thottol R, George A, G L. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. Natl J Physiol Pharm Pharmacol. 2022; 12(6): 823-827. doi:10.5455/njppp.2022.12.04159202221042022



Vancouver/ICMJE Style

Thottol R, George A, G L. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. Natl J Physiol Pharm Pharmacol. (2022), [cited August 03, 2022]; 12(6): 823-827. doi:10.5455/njppp.2022.12.04159202221042022



Harvard Style

Thottol, R., George, . A. & G, . L. (2022) Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. Natl J Physiol Pharm Pharmacol, 12 (6), 823-827. doi:10.5455/njppp.2022.12.04159202221042022



Turabian Style

Thottol, Reema, Ancy George, and Laxmi G. 2022. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 12 (6), 823-827. doi:10.5455/njppp.2022.12.04159202221042022



Chicago Style

Thottol, Reema, Ancy George, and Laxmi G. "Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 823-827. doi:10.5455/njppp.2022.12.04159202221042022



MLA (The Modern Language Association) Style

Thottol, Reema, Ancy George, and Laxmi G. "Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial." National Journal of Physiology, Pharmacy and Pharmacology 12.6 (2022), 823-827. Print. doi:10.5455/njppp.2022.12.04159202221042022



APA (American Psychological Association) Style

Thottol, R., George, . A. & G, . L. (2022) Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 12 (6), 823-827. doi:10.5455/njppp.2022.12.04159202221042022